Item 8.01 Other Events.
On May 24, 2021, NGM Biopharmaceuticals, Inc. issued a press release announcing
topline results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin
in 171 patients with biopsy-confirmed non-alcoholic steatohepatitis with stage 2
or 3 liver fibrosis. A copy of the press release titled "NGM Bio Reports Topline
Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH" is filed
as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Description
99.1 Press release, dated May 24, 2021, titled "NGM Bio Reports Topline
Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH."
104 Cover Page Interactive Data File (formatted in Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses